- Coordinator
- Region Syddanmark, Denmark
- Runs
- 1 June 2026 to 31 May 2030
- Status
- Running
- EU funding
- €16.7m
- Total cost
- €16.7m
- Partners
- 26 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287214
What the project is doing
In the project's own words, from its summary on CORDIS.
AIM-SAFE develops a European multi-agent framework for trustworthy Generative AI in clinical decision support, tackling patient safety challenges in polypharmacy management and oncology treatment optimization. Its modular, locally deployed architecture leverages containerised SLM-powered agents that collaborate on bounded clinical functions, such as adverse drug event prediction, deprescribing support, pharmacogenomic reasoning, and phenoconversion modeling, while operating within hospital environments under robust privacy controls, continuous federated learning workflows, and explainable intelligence, fully aligned with European data governance laws (e.g., GDPR, AI Act, EHDS).
Beyond model development, AIM-SAFE equips researchers and clinicians with the knowledge, tools, and governance frameworks to apply Generative AI responsibly and effectively in practice. AIM-SAFE delivers open-source toolkits, FAIR datasets, and Safety Co-Pilot modules to advance trustworthy healthcare AI, ensuring ethics, transparency, and patient safety. Its key components include the CAFEIN federated learning platform, explainable AI engines enhanced with Reinforcement Learning from Human Feedback loops, and integrated safety governance through the RUC2 framework.
This approach enables privacy-preserving data harmonization across clinical partners, ensuring sensitive data remains under local control while contributing to shared models. The system integrates multimodal biomedical data from EHRs, pharmacogenomic profiles, imaging metadata, and European knowledge databases. By reinforcing European digital sovereignty, reducing reliance on non-EU AI providers, and ensuring full compliance with EU ethical, legal, and regulatory principles, AIM-SAFE transforms clinical decision support into a safe, explainable, and human-centred approach that reduces adverse drug events, improves patient care, and contributes to lower mortality and healthcare costs.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Region Syddanmark | Vejle | Denmark | Coordinator |
| Universitat Wien | Wien | Austria | Participant |
| Cancer Patients Europe | Bruxelles / Brussel | Belgium | Participant |
| European Union Geriatric Medicine Society Aisbl | Bruxelles / Brussel | Belgium | Participant |
| Trinetx Europe NV | Sint-Martens-Latem | Belgium | Participant |
| Ecole Polytechnique Federale De Lausanne | Lausanne | Switzerland | Participant |
| Organisation Europeenne Pour La Recherche Nucleaire | Geneve 23 | Switzerland | Participant |
| Universite De Geneve | Geneve | Switzerland | Participant |
| Apheris Ai GmbH | Berlin | Germany | Participant |
| European Molecular Biology Laboratory | Heidelberg | Germany | Participant |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| D.tsakalidis-G.domalis Oe | Patra | Greece | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Fedder Ai SL | Barcelona | Spain | Third party |
| Universitat De Barcelona | Barcelona | Spain | Participant |
| Centre Hospitalier Universitaire De Toulouse | Toulouse Cedex 3 | France | Participant |
| Agora Labs S.r.l. | Collevecchio (Ri) | Italy | Participant |
| Korea Advanced Institute of Science and Technology | Daejeon | South Korea | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Uniwersytet Jagiellonski | Krakow | Poland | Participant |
| leki.pl sp. z o.o. | Warszawa | Poland | Participant |
| Limited Liability Company Knowledgator Engineering | Kyiv | Ukraine | Participant |
| Sheffield Hallam University | Sheffield | United Kingdom | Participant |
| The Royal Marsden National Health Service Trust | London | United Kingdom | Participant |
| The University of Liverpool | Liverpool | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI